CAS 1005780-62-0

Fórmula: C23H23N7O3

InChI: InChI=1S/C23H23N7O3/c1-13-4-7-16(11-17(13)24-23(32)18-10-14(2)27-29(18)3)33-21-9-8-20-25-19(12-30(20)28-21)26-22(31)15-5-6-15/h4,7-12,15H,5-6H2,1-3H3,(H,24,32)(H,26,31)

Chave InChI: DZFZXPPHBWCXPQ-UHFFFAOYSA-N

SMILES: CC1=C(C=C(C=C1)OC2=NN3C=C(N=C3C=C2)NC(=O)C4CC4)NC(=O)C5=CC(=NN5C)C

TAK-593

CAS: 1005780-62-0

TAK-593

Fórmula: C₂₃H₂₃N₇O₃

Pureza: 99%

Peso molecular: 445.47

Ref: 54-BUP09817

N-(5-((2-(Cyclopropanecarboxamido)imidazo[1,2-b]pyridazin-6-yl)oxy)-2-methylphenyl)-1,3-dimethyl-1H-pyrazole-5-carboxamide

CAS: 1005780-62-0

Fórmula: C₂₃H₂₃N₇O₃

Pureza: 98%

Peso molecular: 445.4738

Ref: IN-DA008TJS

TAK-593

CAS: 1005780-62-0

TAK-593 is an effective VEGFR and PDGFR family inhibitor (IC50s: 3.2, 0.95, 1.1, 4.3, and 13 nM for VEGFR1, VEGFR2, VEGFR3, PDFGRα, and PDFGRβ, respectively).

Fórmula: C₂₃H₂₃N₇O₃

Pureza: 99.37%

Cor e Forma: Solid

Peso molecular: 445.4738

Ref: TM-T16975

TAK-593

CAS: 1005780-62-0

TAK-593 is an activator of the N-terminal signaling domain of the erythropoietin receptor that is selective for the erythropoietin receptor. It inhibits tumor growth and induces apoptosis in cancer cells by inhibiting protein synthesis. TAK-593 has been shown to induce tumor regression in mice with lung carcinomas, prostate carcinomas, and breast carcinomas. It also prevents the development of retinal neovascularization in a rat model of oxygen-induced retinopathy and reduces intraocular pressure in rats with experimental glaucoma. TAK-593 is a potent inhibitor of angiogenesis and vascular permeability.

Fórmula: C₂₃H₂₃N₇O₃

Pureza: Min. 95%

Peso molecular: 445.47 g/mol

Ref: 3D-FQB78062